Schedule of Allocation of Purchase Price (Details) - USD ($) |
Oct. 11, 2024 |
Aug. 11, 2023 |
Mar. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|---|---|
| Assets and liabilities acquired: | ||||
| Goodwill | $ 8,890,624 | $ 23,535,693 | ||
| NAYA Therapeutics [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Common Stock | $ 214,937 | |||
| Series C-1 Preferred | 17,691,000 | |||
| Series C-2 Preferred | 7,457,000 | |||
| Convertible Debenture | 3,934,146 | |||
| Business acquisition cost | 29,598,061 | |||
| Assets and liabilities acquired: | ||||
| Cash | 472,008 | |||
| Other current assets | 40,747 | |||
| Goodwill | 17,656,707 | |||
| AP & accrued liabilities | (3,109,039) | |||
| Debt | (290,362) | |||
| Total assets and liabilities acquired | 29,598,061 | |||
| NAYA Therapeutics [Member] | Trade Names [Member] | ||||
| Assets and liabilities acquired: | ||||
| In process R&D | 257,000 | |||
| NAYA Therapeutics [Member] | In Process Research and Development [Member] | ||||
| Assets and liabilities acquired: | ||||
| In process R&D | $ 14,571,000 | |||
| Naya Acquisition Prefunded Warrants [Member] | ||||
| Business Acquisition [Line Items] | ||||
| NAYA Acquisition Pre-funded Warrants | $ 300,978 |
| X | ||||||||||
- Definition Payments to acquire businesses common stock. No definition available.
|
| X | ||||||||||
- Definition Payments to acquire businesses debenture. No definition available.
|
| X | ||||||||||
- Definition Payments to acquire businesses prefunded warrants. No definition available.
|
| X | ||||||||||
- Definition Payments to acquire businesses series c one preferred stock. No definition available.
|
| X | ||||||||||
- Definition Payments to acquire businesses series c two preferred stock No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|